2095312-08-4
Chemical Structure
PDM-631
- CAS No.: 2095312-08-4
- Formula:C19H19F3N4O2
- Molecular Weight:392.37
IUPAC Name: (S)-3-cyclopropyl-6-methyl-1-(1-(4-(trifluoromethoxy)phenyl)propan-2-yl)-1,7-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
InChIKey: VHMPTEZWTNAXPL-JTQLQIEISA-N
SMILES: FC(F)(F)OC(C=C1)=CC=C1C[C@@H](N2C3=C(C(N=C(N3)C)=O)C(C4CC4)=N2)C
Biological Activity: PDM-631 is a selective and orally active PDE2A inhibitor with blood-brain barrier penetration. PDM-631 exhibits potent inhibitory activity against human and rat recombinant PDE2A with IC50 values of 1.5 nM and 4.2 nM, respectively. PDM-631 increases cGMP levels in the rat cerebral cortex. PDM-631 can be used for the study of schizophrenia and neurodegenerative disorders[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PDM-631 | PDM-631 is a selective and orally active PDE2A inhibitor with blood-brain barrier penetration. PDM-631 exhibits potent inhibitory activity against human and rat recombinant PDE2A with IC50 values of 1.5 nM and 4.2 nM, respectively. PDM-631 increases cGMP levels in the rat cerebral cortex. PDM-631 can be used for the study of schizophrenia and neurodegenerative disorders. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
